(Q57778360)

ORCID Public Data File 2021

author name string

Rafael Zalacain

2

0 references

Cristina Murio

3

0 references

Montserrat Ferrer

4

0 references

Jos?? L Alvarez-Sala

5

0 references

Juan F Masa

6

0 references

H??ctor ??Verea

7

0 references

Fernando Ros

8

0 references

Rafael Vidal

Clinical Drug Investigation

9

0 references

publication date

2003

0 references

published in

0 references

volume

23

0 references

issue

7

0 references

page(s)

439-450

0 references

cites work

Relationship Between Bacterial Flora in Sputum and Functional Impairment in Patients With Acute Exacerbations of COPD

1 reference

12 December 2020

[Recommendations for the care of the patient with chronic obstructive pulmonary disease]

1 reference

12 December 2020

Fluoroquinolone resistance in Streptococcus pneumoniae

1 reference

12 December 2020

Bronchodilator response in chronic obstructive pulmonary disease.

1 reference

12 December 2020

Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective

1 reference

12 December 2020

Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative

1 reference

12 December 2020

Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD

1 reference

12 December 2020

Acute exacerbation of COPD: factors associated with poor treatment outcome

1 reference

12 December 2020

Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice

1 reference

12 December 2020

Quality of life in acute exacerbation of chronic bronchitis: results from a German population study.

1 reference

12 December 2020

Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study

1 reference

12 December 2020

Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group.

1 reference

12 December 2020

The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD.

1 reference

12 December 2020

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

12 December 2020

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients

1 reference

12 December 2020

Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

1 reference

12 December 2020

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society

1 reference

12 December 2020

The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.

1 reference

12 December 2020

Moxifloxacin in the therapy of experimental pneumococcal meningitis

1 reference

12 December 2020

Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group.

1 reference

12 December 2020

Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia

1 reference

12 December 2020

Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria

1 reference

12 December 2020

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

12 December 2020

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

1 reference

12 December 2020

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

1 reference

12 December 2020

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

12 December 2020

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae

1 reference

12 December 2020

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society

1 reference

12 December 2020

Treatment and quality of life in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin

1 reference

12 December 2020

Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin

1 reference

12 December 2020

Pharmacoeconomic Evaluation of Acute Exacerbations of Chronic Bronchitis and COPD

1 reference

12 December 2020

Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study

1 reference

12 December 2020

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes

1 reference

12 December 2020

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

12 December 2020

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

1 reference

12 December 2020

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

12 December 2020

Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group.

1 reference

12 December 2020

Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis

1 reference

12 December 2020

The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

12 December 2020

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

1 reference

12 December 2020